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Objective. To assess awareness of and interest in intrauterine contraceptive device (IUCD) use among HIV-positive women in Cape
Town, South Africa. Design. Cross-sectional survey. Methods. HIV-positive women aged 18 through 45 years presenting for care
at a primary health care clinic in Cape Town, South Africa participated in this study. Consented participants completed a staff-
administered questionnaire in a private setting. Descriptive statistics were generated. Comparisons between demographic and
reproductive health-related variables and IUCD awareness and interest were performed with multiple logistic regression. Analyses
for IUCD interest excluded women with prior surgical sterilization. Results. Of 277 HIV-positive women, 37% were aware of the
IUCD; awareness was independently associated with greater age (adjusted odds ratio (AOR) = 1.15, 95%; confidence interval
(CI): 1.10–1.20) and not switching contraceptive methods in the last year (AOR = 2.45, 95% CI: 1.03–5.83). Following an IUCD
information session, 86% of women (n = 206/240) were interested in IUCD use. IUCD interest was inversely associated with age
(AOR = 0.91, 95% CI: 0.86–0.97) and marginally positively associated with current menstrual bleeding pattern complaints (AOR
= 2.14, 95% CI: 0.98–4.68). Conclusions. Despite low levels of method awareness, HIV-positive women in this setting are frequently
interested in IUCD use, indicating need for programming to expand method access.
1. Introduction
Contraceptive use to prevent unplanned pregnancy is the
most cost-effective means of preventing maternal-to-child
transmission of HIV [1–4]. Systemic hormonal contra-
ceptives and male condoms are among the most popular
contraceptive methods in Sub-Saharan Africa, the global
region with the greatest proportion of HIV-infected women
[5–7]. Some studies have suggested that systemic hormonal
contraceptive method use by HIV-positive women may
increase HIV transmission to male partners and progression
of HIV disease among users, particularly for depot medrox-
yprogesterone acetate (DMPA), though findings are mixed
[8–14]. These findings, coupled with high unmet need for
contraception in Sub-Saharan Africa, have spurred calls for
safe, long-acting reversible contraceptive methods for HIV-
positive women [4, 15].
The intrauterine contraceptive device (IUCD) is a highly
effective, long-acting contraceptive method and is not widely
used in Sub-Saharan Africa, including South Africa [16].
Two studies among reproductive aged women in South
Africa indicate low (26–41%) awareness of the IUCD as a
contraceptive method, despite its inclusion in contracep-
tive method mix and availability at no cost through the
public sector [17, 18]. Both studies found that a majority
(69–74%) of women were interested in IUCD use after
receipt of basic information about the method [17, 18].
However, these studies did not differentiate women by HIV
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status, although other studies indicate that HIV infection
often impacts contraceptive method choice, potentially
resulting in differences in IUCD receptivity [5, 19].
Among HIV-positive women, the safety of the copper
IUCD has been established in terms of both disease pro-
gression and pelvic inflammatory disease incidence [20–23].
A small European case-control trial suggests the lev-
onorgestrel IUCD is also safe for HIV-positive women [24].
Despite the potential role of IUCDs in the method mix
for HIV-positive women, levels of awareness of and interest
in the IUCD among HIV-positive women are not well
understood. Qualitative assessments among HIV-positive
women in South Africa and Kenya indicate that prior IUCD
use is uncommon [25, 26]. Awareness of the IUCD is largely
based on peer-communicated knowledge of negative effects
but does not reflect potential interest in method use with
receipt of correct information [25, 26]. Recent data from
271 HIV-positive Malawian women meeting IUCD eligibility
criteria reflect that 79% were willing to accept the copper
IUCD, even if it was not their first choice for a method but
did not explore reasons impacting decision to use [27]. We
conducted a study to assess awareness level and potential
interest in the IUCD as a contraceptive method as well as
characteristics associated with awareness of and receptivity to
the IUCD among HIV-positive women in Cape Town, South
Africa.
2. Methods
2.1. Setting and Participants. This cross-sectional survey was
conducted at a single clinic in Cape Town, South Africa
between February and June 2011. This facility offers a range
of primary care services, including HIV care and family
planning, to approximately 17,000 individuals [28]. The local
community is predominantly low socioeconomic status, and
the HIV prevalence in this setting among individuals >15
years of age is estimated to be greater than 20% [28].
Eligible participants were women aged between 18 and
45 years who had documented HIV infection, were seeking
family planning or HIV services, and were able to provide
written informed consent.
2.2. Measures. A pretested questionnaire was administered to
all participants in either English or isiXhosa, per participant
preference. The study instrument assessed demographics,
reproductive and HIV health history, partnership status, and
awareness of the IUCD. The question about IUCD awareness
was asked twice, once during an assessment of awareness
of a list of contraceptive methods and once asking solely
about the IUCD. The proportion reporting IUCD awareness
differed by 7% between the two questions. The lower value
is retained in analyses as the second query was performed in
conjunction with other queries about the device. For women
unaware of the IUCD, a brief description of the method,
inclusive of appearance, efficacy, duration, and potential
side-effects, was developed and provided at a midpoint in the
interview. The script content was as follows.
“The IUD is small and looks like a T made
of plastic, and contains copper or a hormone.
The IUD is inserted into the womb to prevent
pregnancy for a period of five years and longer.
It can be removed when someone wants to
have a baby, and then the person can fall preg-
nant immediately. The IUD is inserted and is
removed easily at the clinic. The most common
change associated with the IUD may be the
change in the woman’s menstrual cycle.”
Actual copper and levonorgestrel IUCDs were also shown
to participants at the end of the information session, and
potential interest in IUCD use was assessed through the
query, “Do you think the loop/IUCD sounds like an option
you can consider for contraception?”, followed by the most
important reasons for either positive or negative interest.
Open-ended questions on receptivity and positive and
negative perceptions of potential IUCD use were analyzed
for common themes and coded into close-ended categories;
these data are clearly marked in Results.
2.3. Procedures. Participants were selected consecutively
upon completion of clinic visits during periods when trained
study staff were available. Study staff approached eligible
potential participants within the clinic and asked for interest
in survey participation. Interested women were brought to
a private room to discuss the study and provide written
informed consent.
Following consent, the questionnaire was administered
in the participant’s preferred language by trained inter-
viewers. Participants desiring contraception and not using
a method or those interested in switching methods were
referred to the family planning services within the clinic site;
participants received a food gift certificate (value US$10) for
participation.
The protocol was reviewed and approved by the insti-
tutional review boards of the University of Cape Town and
Columbia University Medical Center.
2.4. Analysis. Descriptive statistics and measures of IUCD
awareness and interest were generated using counts, means,
and proportions. Correlates of IUCD awareness and interest
in use were assessed with logistic regression analysis; strength
of association was assessed in multivariable models to
produce adjusted odds ratios (AORs). All analysis was per-
formed with STATA Version 10 and Version 11.1 (StataCorp,
College Station, TX, USA).
3. Results
Between February and June, 2011, 277 women participated
in this study (data on refusal rates were not collected).
Sociodemographic characteristics and a summary of repro-
ductive and HIV health history are displayed in Table 1.
Participants had a mean age of 32.0 (standard deviation
(SD) ± 6.4) years with most being unemployed (71%) and
having completed at least some secondary school (89%).
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Table 1: Sociodemographic and health characteristics of HIV-positive women participating in a contraceptive preference assessment in Cape

















Number of persons living in household
Just respondent (1) 24 9%
2–5 people 217 79%
6–9 people 31 11%
12–16 people 4 1%
Home type
Informal dwelling/hokkie 243 88%
Home ownership 4 1%
Flat/municipal house 30 11%
Time from HIV diagnosis
<=1 year 57 21%
>1–3 years 53 19%
>3–5 years 56 20%
>5–7 years 46 17%
>7 years 65 23%
Sexually active in last year 239 86%
Of those sexually active (N = 239) in the last year, number of sexual partners in that time period
One partner 211 88%
Two partners 21 9%
Three to five partners 7 3%
Currently in relationship 227 82%
Relationship status
Married, living together 29 13%
Married, not living together 6 3%
Not married, living together 92 41%
Not married not living together 98 43%
Taking antiretrovirals (ARVs) 177 64%
Duration on ARVs
<=1 year 48 27%
>1–3 years 45 25%
>3–5 years 42 23%
>5 years 42 23%
Ever pregnant 254 92%
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Table 1: Continued.
Variable Number Percentage




Four or greater 47 17%








Three to Five 85 33%




Three to Five 76 31%
N = number.
Table 2: Contraceptive method awareness and current and prior contraceptive use among HIV-positive women in Cape Town, South Africa
(N = 277).
Method
Awareness Prior use Current use
N % N % N %
Pill/oral contraceptive 264 95% 97 35% 9 3%
Injectables 277 100% 269 97% 145 52%
IUCD 103 37% 6 2% 0 0%
Diaphragm 28 10% 4 1% 3 1%∗
Male condom 274 99% 261 94% 57 21%∗
Female condom 264 95% 60 22% 4 1%∗
Tubal ligation 258 93% 34 12% 37 13%
Male sterilization 77 28% 2 1% 0 0%
∗
Overall, many (83%, N = 230) participants reported male condom use; statistic reported reflects those using male condoms alone rather than double
coverage. Similarly, 6/10 women using the diaphragm and 33/37 of those reporting female condom use were using other methods concomitantly.
N = number.
IUCD = intrauterine contraceptive device.
Most participants (82%) were in a relationship, with the
majority describing their status as unmarried and either
living with (41%) or without a partner (43%). The mean
time since HIV diagnosis was 4.6 years (SD ± 3.6), and
64% were using antiretroviral therapy (ART) at the time
of interview. Most participants (92%) had been pregnant
previously with a mean of 2.0 (SD ± 1.1) living children
currently.
All participants reported awareness of at least one
contraceptive method, and nearly all (n = 276, 99%) had
previously used a method. Most women (93%, n = 258)
reported current contraceptive use; the most common reason
stated for not using a method was lack of a current sexual
partner. Current method mix, history of prior methods
used, and awareness of specific contraceptive methods are
displayed in Table 2. Of those currently using contraception
(n = 258), most women (89%) reported satisfaction with
and intent to continue use of their current method, while
4% planned to discontinue their method due to desire
for pregnancy (n = 7), or dissatisfaction with method
(n = 2). Another 3% were not satisfied with the method
yet planned to continue use. A majority (78%, n = 202 of
258 currently using contraception) of women reported using
male condoms in conjunction with another method.
Women were queried regarding the most attractive
features of an ideal contraceptive method, with multiple
answers permitted. The most advantageous features of a con-
traceptive method were (of 516 responses) efficacy to prevent
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Table 3: Correlates of intrauterine contraceptive device (IUCD) awareness and interest in IUCD use among HIV-positive women in Cape
Town, South Africa by univariable logistic regression analysis.
Variable (mean, SD)
IUCD aware Not aware OR, 95% CI IUCD interest
Not
interested OR, 95% CI
(n = 103) (n = 174) (n = 206) (n = 34)
Age (years) 35.2± 5.9 30.1± 5.9 1.15, 1.10–1.21 30.7 + 5.8 34.0± 7.4 0.92, 0.86–0.97
Years education 8.9± 2.7 9.6± 2.0 0.88, 0.80–0.98 9.5± 2.1 9.3± 2.6 1.04, 0.89–1.22
Years since HIV
diagnosis
5.1± 3.6 4.4± 3.5 1.06, 0.99–1.13 4.4± 3.4 4.0 ± 3.8 1.03, 0.93–1.16
Total prior
pregnancies
2.8± 1.3 1.9± 1.2 1.68, 1.37–2.06 2.1± 1.3 2.4± 1.6 0.83, 0.64–1.09
Total living children 2.3± 1.2 1.6± 1.1 1.70, 1.35–2.14 1.7 + 1.1 1.9± 1.3 0.84, 0.62–1.15
(%, Number)
Employed 29%, 30 29%, 51 0.99, 0.58–1.69 26%, 53 41%, 14 0.49, 0.23–1.05
Using antiretrovirals 71%, 73 62%, 108 1.49, 0.88–2.51 65%, 133 65%, 22 0.99, 0.47–2.12
Not changing
contraceptive
method in last 12
months
92%, 91 81%, 140 2.86, 1.28–6.67 18%, 38 9%, 3 2.34, 0.68–8.05
More than 1 sexual
partner in last year
9%, 9 11%, 19 0.78, 0.34–1.80 13%, 26 0%, 0 N/A
Currently in
relationship
78%, 80 85%, 147 0.64, 0.34–1.19 84%, 172 74%, 25 1.82, 0.78–4.24
Sexually active in
last year
82%, 84 90%, 156 0.51, 0.25–1.02 89%, 184 77%, 26 2.57, 1.04–6.38
Current menstrual
complaints
45%, 103 53%, 92 0.72, 0.44–1.17 50%, 102 32%, 11 2.05, 0.95–4.42
Regular menstrual
cycle (n = 166) 75%, 53 68%, 87 1.39, 0.72–2.66 69%, 100 50%, 11 2.27, 0.92–5.63
∗
Excludes women previously sterilized.
CI = confidence interval.
n = number.
OR = odds ratio.
SD = standard deviation.
pregnancy (32%), preventing sexually transmitted infections
and/or HIV transmission/reinfection (26%), lasting for long
duration without necessitating a clinic visit for readministra-
tion (11%), causing no menstrual changes (7%), having no
associated weight changes (4%), no associated mood or other
side effects (3%), and having no interaction with ARVs (3%).
Method change in the last year was reported by 42
(15%) women, with the key reasons for changing methods
being desired pregnancy (29%), heavy menstrual bleeding
(12%), irregular menses (10%), and other side effects (10%).
Method change rarely occurred in response to HIV diagnosis
(9%) or ARV initiation (3%). Stated reasons for method
change at the time of HIV diagnosis by 24 women included
concern for how the method would interact with HIV disease
(30%), planned sexual abstinence or cessation of current
relationship (18%), side effects excluding menstrual and
weight changes (17%), desire for pregnancy (13%), or heavy
menstrual bleeding (9%).
Awareness of the IUCD was reported by 37%, with
only the diaphragm and male surgical sterilization having
lower levels of general awareness. Very few (8%) participants
reported having been informed about the IUCD previously
by a medical provider, and fewer were specifically aware
of the copper (4%) or levonorgestrel (3%) IUCD. IUCD
awareness was significantly associated with greater age,
greater numbers of prior pregnancies and living children,
lower education, and lower likelihood of sexual activity
or not switching contraceptive methods in the last year
(Table 3). In multivariable logistic regression analysis, only
increasing age (AOR = 1.15, 95%, confidence intervals,
CI: 1.10–1.20) and not switching contraceptive methods
in the last year (AOR = 2.45, 95% CI: 1.03–5.83) were
independently associated with IUCD awareness.
Following a brief information session on IUCDs, 86%
(n = 206 of 240 women not having been sterilized) were
potentially interested in future IUCD use. Interest in IUCD
use was associated with younger age and being sexually
active in the last year; marginal associations were noted
with being unemployed, having a regular menstrual cycle,
or having perceived menstrual irregularities in bivariate
logistic regression. Of note, all women with more than one
sexual partner in the last year reported interest in the IUCD
(Table 3). In multivariable logistic regression, interest in
IUCD use was independently inversely associated with age
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(AOR = 0.91, 95% CI: 0.86–0.97) and marginally with having
menstrual bleeding pattern complaints (AOR = 2.14, 95%
0.98–4.68). Those interested in the IUCD were queried about
the positive features of the IUCD as an open-ended question,
and the common features ranking highest (of 408 total
responses, multiple responses were allowed) were duration of
action (42%), reversible method/rapid restoration of fertility
(33%), efficacy at preventing pregnancy (12%), and ease
of insertion/removal (10%). Based on potential menstrual
changes, particularly with the levonorgestrel IUCD, willing-
ness to use the IUCD with accompanying menstrual changes
was queried. Nearly all interested participants (n = 204)
desired the IUCD if oligo/amenorrhea resulted, while only 8
were willing to use an IUCD if menstrual bleeding increased.
Many (60%, n = 143) believed their partner would be
receptive to the IUCD.
4. Discussion
This study demonstrates low IUCD awareness relative to
other methods, particularly injectable contraceptives, and
high prevalence of IUCD interest among HIV-positive
women. These results are quite similar to those among
general clinical populations in South Africa and suggest that
there is significant potential to promote the IUCD in this
setting [17, 18].
We found that older women were more likely to be aware
of the IUCD before the study, possibly based on exposure to
information about a variety of contraceptive methods over
time. We speculate that the association between awareness
and not changing contraceptive methods in the last year
may reflect quality of counseling provided by medical
staff, inclusive of a comprehensive presentation of available
options. Alternately, women may be more likely to continue
methods with which they have a degree of comfort provided
by peer experience or reinforcement. Further investigation
is needed to determine factors associated with method
continuation among this patient population. The very low
rate of prior personal IUCD use or reported mention of
the IUCD by medical providers likely contributes to lower
overall awareness or prior interest in use; peers may be the
predominant information source. IUCD information relayed
by HIV-positive women from peer sources has been noted
to be of questionable accuracy; inaccurate information in
this group and among South African women have negatively
predisposed some women toward the IUCD [17, 25, 26].
Despite low levels of awareness, many women were
receptive to IUCD use after receiving an explanation of
the method, similar to levels recorded in other South
African studies [17, 18]. Younger age was associated with
interest in the IUCD, possibly due to reduced potential
exposure to negative information from peers or due to the
appeal of IUCD longevity and reversibility without need
for return clinic visits. Sexual activity was also associated
with interest in IUCD use, with those more sexually active
being more receptive to its use, indicating self-awareness of
pregnancy risk. Though reported IUCD interest was high, it
is important to note that interest is not always correlated with
actual method uptake [29]. In a similar vein, stated preferred
methods may not be the only method a woman is willing
to accept. This is particularly important with regard to the
IUCD due to low levels of awareness. For example, in Malawi,
HIV-positive women stating preference for other contracep-
tive methods were willing to accept the IUCD, potentially
indicating the role for well-informed counseling [27].
Participants perceived many advantages to the IUCD,
with duration of action and reversibility being the most
important features in an environment where contraceptive-
induced menstrual bleeding disturbances are common as the
predominant method is the hormonal injectable. Overall,
the IUCD appears to be a useful option for this patient
population as the most desirable qualities of a contraceptive
method were efficacy in preventing pregnancy, prevention
of sexually transmitted infections or HIV reinfection, and
long duration of action. The IUCD possesses two of these
qualities, and dual method use with male condoms is a
reportedly normative behavior among this patient group.
Of note, changing methods in response to HIV diagnosis
or disease progression was uncommon, and considerations
relative to impact on HIV disease, with the exception of
reinfection or transmission to partners, were relatively less
important than considerations surrounding contraceptive
efficacy and duration when mentioning desirable method
attributes.
However, bleeding changes were a common reason
reported for method discontinuation, second only to desir-
ing pregnancy, and this sensitivity deserves introspection
when considering the IUCD for HIV-positive women [30].
Though there was a marginal positive association between
women with reported abnormal menstrual bleeding and
IUCD interest, the association may reflect dissatisfaction
with the current method and desire to change rather than
a considered preference for the IUCD. The most common
reason for discontinuation of the copper IUCD is increased
menstrual bleeding [31], a side effect which the current
study participants reported would prevent use of the IUCD.
However, participants were willing to use an IUCD that may
cause oligo/amenorrhea, a side effect profile similar to that
of the hormonal injectable, the most common nonbarrier
method used by participants. Though the levonorgestrel
IUCD is not currently available in the public sector system
and the high cost of the device is likely prohibitive for many
participants, this population is likely to benefit from such
a method. Advocacy and further research on the safety and
acceptability of the levonorgestrel IUCD for HIV-positive
women are indicated to improve method choice for this
population.
These data should be viewed in light of several lim-
itations. First, participants were enrolled through conve-
nience sampling at one clinic in urban Cape Town, and
the generalizability of the findings is unclear. This study
was performed in Western Cape, the province with the
second highest contraceptive prevalence rate in South Africa,
[32] and reported contraceptive use rates and interest in
the IUCD may be somewhat higher than elsewhere in
South or sub-Saharan Africa. We did not collect data on
reasons for attending the clinic and do not have data
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on number and reasons for refusals to participate. In
addition, the questionnaire was interviewer administered,
potentially resulting in socially desirable responses such as
overreporting of contraceptive and condom use. However,
reported contraceptive prevalence was similar to results in
South Africa reported by Gutin et al. [17]. Prospective
studies are needed to evaluate use acceptability of the IUCD
for HIV-positive women, particularly in comparison with
other methods. Last, provider awareness, knowledge, and
perceptions regarding IUCD safety for HIV-positive women
were not assessed and potentially presents an opportune
route to improve IUCD use, as noted by van Zijl et al.
[18]. Future studies should also include both HIV and
reproductive health care provider perspectives for greater
insight into the contraceptive decision-making process.
5. Conclusions
In summary, these data suggest that HIV-positive women
may be receptive to IUCD use despite low levels of method
awareness. Our data support efforts to expand contraceptive
method mix for this population through programming to
promote IUCD use directed at providers and patients.
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